Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  ibrutinib
Find trials that include:  Any drugs shown
Results 1-25 of 39 for your search:
Start Over
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CR100955, NCI-2013-02262, 2012-004225-24, PCI-32765CAN3001, NCT01804686
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients with Previously Untreated Chronic Lymphocytic Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 65 and over
Trial IDs: A041202, NCI-2013-01220, ALLIANCE A041202, NCT01886872
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: E1912, NCI-2014-00118, ECOG-E1912, NCT02048813
Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: PCYC-1127-CA, NCI-2014-01363, NCT02165397
A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve CLL or SLL
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Age: 18 and over
Trial IDs: PCYC-1130-CA, NCI-2015-00662, NCT02264574
Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: UTX-IB-301, NCI-2015-00855, NCT02301156
Ibrutinib before and after Stem Cell Transplant in Treating Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A051301, NCI-2015-00668, BMT CTN 1201, NCT02443077
Study of the Bruton's Tyrosine Kinase Inhibitor in Combination With Carfilzomib (Kyprolis™), in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PCYC-1119-CA, NCI-2014-00660, PCI-32765 [Sponsor], NCT01962792
Ibrutinib in Combination With Lenalidomide, With and Without Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PCYC-1123-CA, NCI-2014-00826, NCT02077166
Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PCYC-1124-CA, NCI-2014-01504, NCT02142049
Ibrutinib in Treating Patients with Refractory or Recurrent Primary or Secondary Central Nervous System Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-184, NCI-2014-02562, NCT02315326
Ibrutinib in Treating Patients with Recurrent or Stage IV Non-small Cell Lung Cancer with an EGFR Mutation
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0602, NCI-2015-00124, NCT02321540
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PCYC-1136-CA, NCI-2015-00777, NCT02401048
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PCYC-1135-CA, NCI-2015-00591, NCT02403271
Bcl-2 inhibitor GDC-0199 in Combination with Obinutuzumab and Ibrutinib in Treating Patients with Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU-14266, NCI-2015-00252, ML29533, NCT02427451
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PCYC-1129-CA, NCI-2014-01591, NCT02195869
Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: PCYC-1103-CA, NCI-2011-00986, PCI-32765, NCT01109069
Ibrutinib in Treating Patients with Relapsed Hairy Cell Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU-12200, NCI-2013-00826, 9268, NCT01981512, 14-C-0004, NCT01841723
Ibrutinib with or without Rituximab in Treating Patients with Relapsed Chronic Lymphocytic Leukemia
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2013-0703, NCI-2014-00989, NCT02007044
Ibrutinib in Treating Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-0459, NCI-2014-00886, 9543, NCT02129062
Ibrutinib after Intensive Induction in Treating Patients with Previously Untreated Mantle Cell Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 14H06, NCI-2014-01777, PCI-32765MCL2003, STU00098385, NCT02242097
Start Over